|本期目录/Table of Contents|

[1]张瑞宁,魏 芳,王立华,等.碳酸镧治疗维持性血液透析高磷血症患者疗效观察[J].天津医科大学学报,2014,20(04):303-305.
点击复制

碳酸镧治疗维持性血液透析高磷血症患者疗效观察(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
20
期数:
2014年04期
页码:
303-305
栏目:
临床医学
出版日期:
2014-07-08

文章信息/Info

Title:
-
文章编号:
1006-8147(2014)04-0303-03
作者:
张瑞宁魏 芳王立华姜埃利
(天津医科大学第二医院血液净化中心,天津 300211)
Author(s):
-
关键词:
维持性血液透析高磷血症碳酸镧
Keywords:
-
分类号:
R692
DOI:
-
文献标志码:
A
摘要:
目 的:观察碳酸镧治疗维持性血液透析(MHD)高磷血症患者的短期疗效及不良反应。方法:对31例MHD高磷血症患者使用福斯利诺治疗,用药前及用药后1 月检测血磷(P)、钙(Ca)、甲状旁腺素(PTH)、白蛋白(Alb)及血红蛋白(Hb),评价治疗效果;观察有无不良反应。结果:(1)用药后1 月患者血P较治疗前下降,差异有统计学意义(P<0.05);血Ca、PTH、Alb及Hb治疗前后差异无统计学意义(P>0.05)。(2)31例患者达标3例,好转18例,有效21例,总有效率为67.7%,无效9例,不良反应1例。结论:碳酸镧用于短期治疗MHD患者的高磷血症有效且耐受性良好,但仍需严密观察其不良反应。
Abstract:
-

参考文献/References:

[1] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815

[2] Hoshina M, Wada H, Sakakura K, et al. Determinants of progression of aortic valve stenosis and outcome of adverse events in hemodialysis patients[J]. J Cardiol, 2012, 59(1): 78

[3] Noordzij M, Cranenburg E M, Engelsman L F, et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients[J]. Nephrol Dial Transplant, 2011, 26(5), 1662

[4] Palmer S C, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis[J]. JAMA, 2011, 305(11): 1119

[5] Danese M D, Belozeroff V, Smirnakis K, et al. Consistent control of mineral and bone disorder in incident hemodialysis patients[J]. Clin J Am Soc Nephrol, 2008, 3(5): 1423

[6] Nikolov I G, Joki N, Nguyen-Khoa T, et al. Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice[J]. Nephrol Dial Transplant,2012, 27(2): 505

[7] Vemuri N, Michelis M F, Matalon A. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study[J]. BMC Nephrol, 2011, 12: 49

[8] Goto S, Komaba H, Moriwakiet K, et al. Clinical Efficacy and Cost-Effectiveness of Lanthanum Carbonate as Second-Line Therapy in Hemodialysis Patients in Japan[J]. Clin J Am Soc Nephrol, 2011, 6(6): 1375

[9] Shigematsu T, Tokumoto A, Nakaoka A, et al. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia[J]. Ther Apher Dial, 2011, 15( 2) : 176

[10] Toussaint N D, Lau K K, Polkinghorne K R, et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial[J]. Nephrology, 2011, 16(3): 290

相似文献/References:

[1]孟 甲,魏 芳,王立华,等.终末期肾病血液透析相关性腹水发生情况及其相关危险因素的探讨[J].天津医科大学学报,2017,23(02):112.

备注/Memo

备注/Memo:

基金项目 天津市医药卫生2012年度重点攻关项目基金资助(12KG136)

作者简介 张瑞宁(1982-),女,医师,硕士,研究方向:肾脏病血液净化;通信作者:魏芳,E-mail:weiwei258@vip.sina.com。

更新日期/Last Update: 2014-06-06